often with PSA kinetics and serial biopsy. Any progression of the cancer while patients are monitored appears unlikely to threaten length of life (6). Through this report we aim at facilitating dissemination of information on the critical role pathological parameters play in identifying appropriate candidates for AS.
INTRODUCTION
The overwhelming majority of men diagnosed with prostate cancer (PCa) opt for primary curative therapy, such surgery to remove the prostate, i.e., radical prostatectomy, or radiation therapy to eradicate the tumor. However, most PCas are indolent and the number of newly diagnosed cases far outnumbering that of lethal cases (1) . The magnitude of this so-called overdiagnosis, where cancers are identified that would never progress or cause harm to the patient if left untreated, ranges from 15% to 84% of new PCa cases (2, 3) . Patients are exposed to the risk of overtreatment. Even if overtreatment is avoided, overdiagnosis induces anxiety associated with the new cancer diagnosis, often resulting in further tests and expenses, and confers upon the patient a 'cancer survivor' label he carries for the rest of his life (4) . Male offspring may worry about familial inheritance and increased risk of the disease. Given the indolent course of many PCa detected by PSA screening (5) , active surveillance (AS) has emerged as an initial management alternative, thus men avoiding the side effects of PCa treatment. Under most AS strategies, patients undergo careful monitoring of the cancer, most biopsy (20 core or more based on prostate volume) (11) . Anterior gland should be included in the repeated biopsy. Magnetic Resonance imaging can be performed before re-biopsy since the negative predictive value for significant cancer raise 95%, however the positive predictive value is lower. Men who experience early upgrading likely represent initial sampling error, whereas later upgrading may reflect tumor dedifferentiation.
THE ROLE OF THE PATHOLOGIST
The essential reporting items for cancer containing prostatic needle biopsies are listed in Table 3 . Tumor extent measurements and the Gleason score are the most important pathologic parameters in needle biopsies determining eligibility for AS protocols.
Tumor extent measurements
There is no consensus on the best tumor quantification methods, which include: cancer percentage in each core, greatest percentage of cancer, cancer length in each core, greatest length of cancer (GLC), total percentage of carcinoma in all cores, total length carcinoma in all cores, fraction of positive cores, total carcinoma surface area and total percentage of carcinoma surface area in all cores. Tumor measurements are performed as a visual estimate or using an ocular micrometer or other morphometric measurement such as computerized methods. Visual estimation of percentage without morphometric measurements is commonly performed, although many recent studies do not actually describe whether visual estimation or morphometric measurements were used. Some use a regular ruler or the side graticule available on most microscopes for estimation of length and percentage. The knowledge of the diameter of the field at each magnification for the microscope used to measure tumor extent can also help maximize accuracy of visual estimation of length. In a recent abstract, Mahamud et al. found no overall difference between visual estimation and measurement when determining percent involvement of prostate biopsies assessed only by whole slide images. However, there was a significant difference between the two methods when they considered a subset of cores deemed to have 40-60% involvement by visual estimation. It is unclear whether the accuracy of visual estimation of an image can be compared with that of a tissue core on a glass slide on a microscope. Data are conflicting whether morphometric measurements are superior to visual estimation and whether differences in the two methods would affect clinical management. Computerized morphometric measurements are considered time-consuming and not practical for most pathologists. Measurements of core length given in gross descriptions should not be used as these may not always be accurate. A few studies have assessed the value of the different methods of tumor extent measurement in prostate needle biopsy in predicting pathological stage or prognosis. Quintal et al. (12) found that total percentage of carcinoma in all cores and number and percentage of cores with cancer were significantly stronger than other methods such as greatest percentage of cancer or length in a single core in predicting biochemical recurrence. Total percentage of carcinoma in all cores had the strongest correlation and when combined with preoperative PSA and Gleason score improved prediction of pT3 in multivariate analysis. This was also independent for risk of biochemical recurrence. Bismar et al. (13) found that although many tumor measurements such as greatest percentage of cancer, total tumor length in millimeters, fraction of positive cores and total percentage of carcinoma were significant in univariate analysis, only the fraction of positive cores was significant in multivariate analysis in predicting pT3 disease or positive margins. In this study all the measures were highly related to one another in a formal correlation analysis. Park et al. (14) examined the significance of the number of cores positive for cancer, percentage of positive biopsy cores, total linear cancer length, total percentage of carcinoma and maximum cancer core length and found that, when considering PSA and Gleason score, none were significant in predicting pT3 disease in multivariate analysis. In a study by Brimo et al. (15) , it was found that the fraction of positive cores, total percentage of carcinoma and both total and greatest cancer core length were closely associated with pathological stage and biochemical failure. The fraction of positive cores was found to be the factor most closely associated with pT3 disease in radical prostatectomy. Correlating needle biopsy cancer measurements with tumor volume in radical prostatectomy, Poulos et al. (16) found that the highest percentage of carcinoma in any biopsy site, percentage of adenocarcinoma at the biopsy site with the highest grading, the number of positive biopsy sites and tumor bilaterality were significant with the percentage of biopsy sites positive for disease the most significant predictor of tumor volume. In a study by Lewis et 
PROBLEMS ASSOCIATED WITH TUMOR EXTENT MEASUREMENTS

Measuring discontinuous foci of cancer
When measuring discontinuous foci of cancer on a prostate needle biopsy core, the pathologist has to specify presence of discontinuous foci, linear extent in aggregate of discontinuous foci, percentage involvement of the core, and the core length spanned by discontinuous foci. 
Tissue core and tumor fragmentation
Concerning the number of cores per cassette, the ideal would one core per cassette. Two biopsies from the same location could be embedded together. It has been shown that simultaneous inclusion of 3 biopsies in the same cassette can lead to the loss of a mean length of 1.15 cm of assessable tissue which corresponds to the average length of one prostate biopsy. When multiple cores are submitted in a single cassette or jar by the urologist and processed in a single cassette, many pathologists give the overall percentage of cancer for the entire slide as opposed to the percentage for each individual core. At the Pathology Laboratory of United Hospitals, Ancona, we attempt to give the percentage of cancer per core for each individual positive core, regardless of how many cores are on a given slide.
When reporting biopsies with multiple cores in the same jar, the pathologist has to provide linear measurement (in millimeters) or linear extent (as percentage) of prostatic tissue involved for the most involved core and the overall linear percentage or measurement in millimeters of tissue submitted from the site(s) with cancer. If there are multiple fragmented small cores containing cancer, an accurate assessment of percentage of cancer per core cannot be determined, and only an overall percentage of cancer per fragmented specimen can be noted. In this scenario, one cannot even determine with certainty the number of positive cores. There is evidence in the literature that there is a greater tendency to core fragmentation when > 1 core is submitted in a container. It is our experience that needle biopsies collected onto gauze or paper are more likely to fragment. Assessment of number of cores involved by PCa is difficult in the presence of core fragmentation. A comment should be made suggesting that the urologist/clinician obtaining the biopsy is in the best position to make determination of number of cores involved based on the original submission of number of cores, and, if necessary, to undertake clinico-pathologic correlation (19) .
Minimum acceptable core length
Currently there is no definition for adequate or minimum acceptable core length. The percentage of cancer in a short core (e.g. < 5-10 mm) versus that in a sufficiently long core mean entirely different tumor lengths. This has implications for interpretation of percent core involvement in the setting of AS. Since percent core involvement is based only on total length of prostatic parenchyma, non-prostatic elements should not be included in total core length assessment.
GLEASON SCORE
The previous decade has seen considerable change in practice relating to 
SITUATIONS THAT SHOULD EXCLUDE A PATIENT FROM AS
The presence of perineural invasion does not represent an exclusion criterion. However, there are rare pathologic situations that should likely exclude a patient from AS:
• Histologic types: prostatic adenocarcinoma with predominant ductal carcinoma histology, sarcomatoid carcinoma, small cell carcinoma • Intraductal carcinoma without invasive carcinoma • Extraprostatic extension in needle biopsy • Lymphovascular invasion in needle biopsy.
CONCLUSIONS
Given the overdiagnosis and overtreatment of low risk prostate cancer, AS should be a ubiquitously adopted and formalized strategy. Men who experience early upgrading likely represent initial sampling error, whereas later upgrading may reflect tumor dedifferentiation. There are several issues and key questions that arise from the combined clinico-pathologic experience from formal and informal AS treatment management strategies that would be applicable to the management of prostate cancer patients outside of academic centers and clinical trials. These need to be resolved over the next few years to tighten criteria of selection for patients contemplating AS and their subsequent management.
